Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by specific organ manifestations and the production of autoantibodies to nuclear antigens. SLE can induce severe organ damage and carries the risk of fatal outcome. During recent years, no major progress has been made regarding new treatment options except for the introduction of mycophenolate mofetil. Therefore, the results of several large clinical trials using biological agents for treatment of SLE were hopefully awaited. Yet, the application of abatacept, belimumab and rituximab, respectively, to non-renal or renal lupus patients surprisingly has not been successful. Other studies using different agents have not been completed yet. Nevertheless, the results available so far will have a significant impact on the design of future clinical trials and will stimulate the debate on new targets for treatment of SLE.
Keywords: Systemic lupus erythematosus, biologics, clinical trials
Current Drug Discovery Technologies
Title: Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Volume: 6 Issue: 4
Author(s): Johann O. Schroder and Rainald A. Zeuner
Affiliation:
Keywords: Systemic lupus erythematosus, biologics, clinical trials
Abstract: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by specific organ manifestations and the production of autoantibodies to nuclear antigens. SLE can induce severe organ damage and carries the risk of fatal outcome. During recent years, no major progress has been made regarding new treatment options except for the introduction of mycophenolate mofetil. Therefore, the results of several large clinical trials using biological agents for treatment of SLE were hopefully awaited. Yet, the application of abatacept, belimumab and rituximab, respectively, to non-renal or renal lupus patients surprisingly has not been successful. Other studies using different agents have not been completed yet. Nevertheless, the results available so far will have a significant impact on the design of future clinical trials and will stimulate the debate on new targets for treatment of SLE.
Export Options
About this article
Cite this article as:
Schroder O. Johann and Zeuner A. Rainald, Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges, Current Drug Discovery Technologies 2009; 6 (4) . https://dx.doi.org/10.2174/157016309789869010
DOI https://dx.doi.org/10.2174/157016309789869010 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cholecystokinin-8 and Nerve Growth Factor: two Endogenous Molecules Working for the Upkeep and Repair of the Nervous System
Current Drug Targets - CNS & Neurological Disorders Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Insights into the Pathogenesis of Type 1 Diabetes A Hint for Novel Immunospecific Therapies
Current Molecular Medicine Inhibitors of Membrane Receptors Involved with Leukocyte Extravasation
Mini-Reviews in Medicinal Chemistry CCR2 Antagonists
Current Topics in Medicinal Chemistry Ganglioside Mimicry as a Cause of Guillain-Barre Syndrome
CNS & Neurological Disorders - Drug Targets The Ca2+-Activated K+ Channel of Intermediate Conductance:A Molecular Target for Novel Treatments?
Current Drug Targets Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design Nucleic Acid Enzymes as a Novel Generation of Anti-gene Agents
Current Molecular Medicine The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery IL-27: Friend or Foe in the Autoimmune Diseases
Current Immunology Reviews (Discontinued) Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Type I Interferon as a Target of Treatment in SLE
Endocrine, Metabolic & Immune Disorders - Drug Targets